Moderna secures US approval for its first mRNA flu vaccine for adults 50+, overcoming initial Trump administration hesitations
Executive summary: Moderna obtained US regulatory approval for its first mRNA influenza vaccine, authorized for adults aged 50 and above, after earlier reservations from the Trump administration. This approval validates Moderna’s mRNA platform beyond COVID-19, opening a major market in seasonal flu prevention and potentially shifting dynamics in the vaccine industry.
Who is involved: Moderna, US Food and Drug Administration (FDA), and public health authorities overseeing vaccine authorization.
Likely next: Launch of the vaccine in US markets, potential expansion to younger age groups, and increased competition with established flu vaccine producers like Sanofi, GSK, and CSL Seqirus.
Moderna has received authorization from the US administration for its mRNA-based influenza vaccine, initially met with reluctance during the Trump era but now cleared for use in adults aged 50 and older. The approval marks a milestone in Moderna’s expansion beyond COVID-19 vaccines into seasonal infectious disease prevention using its mRNA platform. The decision follows positive clinical data and regulatory review, signaling confidence in the technology’s applicability to flu prophylaxis. This development could accelerate adoption of mRNA vaccines in routine immunization schedules and increase competitive pressure on traditional flu vaccine manufacturers.
What's next — scenarios
Platform Expansion & Market Penetration (50%)
Moderna successfully diversifies revenue streams, reducing dependency on COVID-19 booster cycles.
- High uptake rates in 50+ demographic in Q4/Q1
- Positive quarterly guidance regarding non-COVID mRNA products
Regulatory & Political Friction Re-emergence (30%)
Slowed commercial rollout due to political skepticism or localized reimbursement hurdles.
- Delayed CDC recommendation updates
- Legislative scrutiny regarding mRNA manufacturing subsidies
Traditional Manufacturer Counter-Offensive (20%)
Erosion of Moderna's projected market share as legacy players launch high-efficacy protein-based alternatives.
- Aggressive pricing wars from Sanofi or GSK
- Clinical data showing non-inferiority of traditional flu shots in older adults
What to watch
- Q4/Q1 seasonal flu vaccination uptake data
- Moderna's next earnings call guidance on non-COVID pipeline
- CDC immunization schedule update announcements (next 60 days)
- FDA/Regulatory comments on mRNA safety profiles in elderly populations
Timeline
- — Vaccin contre la grippe : Moderna obtient l’aval de l’administration américaine pour son premier sérum à ARNm (Le Figaro — Économie)
Analysis — what this means
Likely next events
- Moderna to begin commercial distribution of the mRNA flu vaccine in the US Q4 2026
- FDA to review pediatric indications for the vaccine by mid-2027
- Sanofi and GSK to announce updated mRNA flu vaccine timelines by Q1 2027
Sectors affected
- Pharmaceuticals
- Vaccines
- mRNA therapeutics
Regulatory implications
- CDC likely to include Moderna’s flu vaccine in seasonal immunization recommendations for 50+
- HHS to monitor real-world effectiveness and safety post-licensure
Historical parallels
- FDA approval of first mRNA COVID-19 vaccines (Pfizer/BioNTech, Moderna) in December 2020
- Licensure of FluMist quadrivalent nasal spray vaccine in 2003 as a non-egg-based flu alternative
- Approval of Shingrix recombinant zoster vaccine in 2017, marking a shift to subunit vaccine technology
Key entities
Sources
- Vaccin contre la grippe : Moderna obtient l’aval de l’administration américaine pour son premier sérum à ARNm — Le Figaro — Économie
Related cases
- Major tech and biotech stocks enter buy zones as broader indices hold steady
- Suze Orman says a breakup saved an investor more than Moderna's 180% stock surge
- Moderna's market valuation jumps $30 billion on confidence in its cancer vaccine successes
- Moderna’s mRNA melanoma vaccine success drives 176% stock jump, validating cancer immunotherapy platform
- Jim Cramer’s renewed endorsement of Moderna signals growing confidence in its mRNA pipeline and potential stock upside
- US experts endorse Moderna's first mRNA flu vaccine, paving the way for a new mRNA seasonal shot